Die FICO-Datenschutz-Regeln erläutern die Erfassung und Verwendung von Cookies durch FICO. Cookies helfen uns, Ihre Einstellungen zu speichern, um Ihnen eine bessere Benutzererfahrung zu bieten, die Leistung der Website zu bewerten, zu überwachen und zu verbessern und unseren Partnern zu ermöglichen, bei Ihnen Werbungen zu schalten. Sie können die Cookies deaktivieren, indem Sie die Einstellungen in Ihrem Browser ändern, und Sie können uns anweisen, Cookie-Daten nicht an Dritte weiterzugeben. Mit der Nutzung dieser Website stimmen Sie der Verwendung von Cookies wie in den FICO-Datenschutz-Regeln beschrieben zu.
21. Mai 2007
(Minneapolis, Minnesota, USA) - Fair Isaac Corporation (NYSE:FIC), the leading provider of analytics and decision management technology, announced today that VCA Antech Incorporated (NASDAQ:WOOF), a leading animal healthcare company, will be the exclusive U.S. distributor of FastPanelTM diagnostic products and services for companion animals, Fair Isaac's breakthrough approach to diagnosing infectious disease in cats, dogs and other species.
FastPanel™ line of diagnostic products is the first commercial offering released by Fair Isaac's bioanalytics initiative.
"We searched for the best partner and found a great match in VCA Antech, the premier animal healthcare company in the nation," said Jim Kalustian, vice president of the Healthcare, Pharmaceuticals and Government Business Unit at Fair Isaac. "With its extensive network of veterinary diagnostic laboratories and its reputation for high quality service and support, VCA Antech is the ideal partner to get our technology into the marketplace quickly."
"We are excited to become the exclusive distributors for Fair Isaac's new FastPanel diagnostics," said Mr. Josh Drake, Executive VP of VCA Antech. "This technology promises to significantly improve how infectious diseases in companion animals are diagnosed in this country. We look forward to applying its benefits to some vexing diagnostic challenges and bringing compelling FastPanel offerings to market this year." By applying advanced pattern recognition methodologies on genetic data, Fair Isaac's bioanalytics identify sequences with unique properties found within the DNA and RNA of parasites, viruses and bacteria. These patented sequences, called primers, are synthesized and delivered to laboratories for use in molecular diagnostic tests to detect the organisms causing infectious disease. The primers are the key component in the polymerase chain reaction (PCR), a process which allows labs to amplify and detect minute quantities of genetic material, providing a high degree of sensitivity for diagnosis. Fair Isaac's FastPanel primer sets are optimized for parallel processing, so that labs can economically analyze animal samples for many diseases at once.
Dr. Scott Moroff, VP and Chief Medical Officer of Antech Diagnostics, said, "Veterinarians face significant diagnostic challenges in differentiating amongst infectious agents responsible for disease affecting many organ systems. Fast Panel will facilitate the diagnostic process by providing a unique platform for rapid and economical testing of a variety of pathogens on a single sample. The ability to perform multiple assays on a single sample will lead to faster diagnosis and treatment, and is particularly important for our smaller companion animals."
FastPanel diagnostic products break new ground for the veterinary industry in several ways. Even though it tests for multiple pathogens, it requires only the same type of animal samples presently used in conventional, single-pathogen laboratory tests. Also, FastPanel diagnostic products test directly for the presence of pathogens and parasites, thus enabling detection of early-stage infections before antibody tests are able to. For more information about Fair Isaac's FastPanel technology, please visit www.fast-panel.com.
About Fair Isaac Fair Isaac Corporation (NYSE:FIC) makes decisions smarter. The company's solutions and technologies for Enterprise Decision Management give businesses the power to automate more processes and apply more intelligence to every customer interaction. Through increasing the precision, consistency and agility of their decisions, Fair Isaac clients worldwide increase sales, build customer value, cut fraud losses, manage credit risk, reduce operational costs, meet changing compliance demands and enter new markets more profitably. Founded in 1956, Fair Isaac powers hundreds of billions of decisions per year in financial services, insurance, telecommunications, retail, consumer branded goods, healthcare and the public sector. Fair Isaac also helps millions of individuals manage their credit health through the www.myFICO.com website.
About VCA AntechVCA Antech, Inc. (Nasdaq:WOOF), operates and manages the largest networks of freestanding veterinary hospitals and veterinary-exclusive clinical laboratories in the country. VCA Laboratory operates a network of 31 veterinary diagnostic laboratories that provide testing and consulting services used by veterinarians in all 50 states in the detection, diagnosis, evaluation, monitoring, treatment, and prevention of diseases and other conditions affecting animals. VCA Animal Hospitals employs more than 1.400 qualified veterinarians at over 375 animal hospitals in 38 states, offering a full range of general medical and surgical services for companion animals, as well as specialized treatments including oncology, ophthalmology, cardiology and neurology. Dedicated to the provision of compassionate and comprehensive veterinary care, VCA also provides advanced diagnostic services. Statement Concerning Forward-Looking Information Except for historical information contained herein, the statements contained in this press release that relate to Fair Isaac, including statements regarding its FastPanelTM product offering and the benefits to be derived from this offering, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including any unforeseen technical difficulties related to the implementation, use and functionality of the offering, the risks that customers will not perceive material benefits from the offering, failure of the product to deliver the expected results, the possibility of errors or defects in the offering, legal damages arising from product liability claims, and other risks described from time to time in Fair Isaac's SEC reports, including its Annual Report on Form 10-K for the year ended September 30, 2006, and its quarterly report on Form 10-Q for the period ended March 31, 2007. Forward-looking statements should be considered with caution. If any of these risks or uncertainties materializes or any of these assumptions proves incorrect, Fair Isaac's results could differ materially from Fair Isaac's expectations in these statements. Fair Isaac disclaims any intent or obligation to update these forward-looking statements.
Europa, Naher Osten und Afrika
+44 (0) 209-940-8719
+1 786 482 7231
+55 11 97673-6583